AARTI DRUGS LTD. (AARTIDRUGS) financials

AARTI DRUGS LTD. (AARTIDRUGS) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations.[1]It is exporting its API's and Speciality chemicals to over 100 countries across the globe.[2]

Market Cap: ₹3,775Cr.
Current Price: ₹414
Stock P/E: 21.8
ROE: 12.7%
ROCE: 11.7%
Book Value: ₹154
Dividend Yield: 0.48%
52W High / Low: ₹534/319

In Jun 2026, AARTI DRUGS LTD. (AARTIDRUGS) reported sales ₹627 Cr and net profit ₹51 Cr.

Annual TTM: sales ₹2,367 Cr, net profit ₹171 Cr.

Shareholding: Promoters 54.43% (Jun 2026), FIIs 1.52% (Jun 2026), DIIs 10.29% (Jun 2026), Public 33.76% (Jun 2026), No. of Shareholders 1,43,476% (Jun 2026).

AARTIDRUGS quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	543	515	623	521	579	529	632	627
Expenses	484	454	534	457	504	486	552	536
Operating Profit	60	60	89	64	75	42	79	92
OPM %	11%	12%	14%	12%	13%	8%	13%	15%
Other Income	0	11	2	0	0	1	1	-2
Interest	7	8	7	7	6	7	7	7
Depreciation	12	12	12	12	14	15	15	15
Profit before tax	41	52	71	45	56	22	59	68
Tax %	26%	26%	13%	-7%	25%	-56%	23%	25%
Net Profit	30	39	61	49	42	34	45	51
EPS in Rs	3.33	4.22	6.74	5.33	4.58	3.71	4.93	5.57
Raw PDF	—	—	—	—	—	—	—	—

AARTIDRUGS profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	1,635	1,915	2,251	2,498	2,267	2,174	2,260	2,367
Expenses	1,387	1,511	1,930	2,212	1,998	1,908	1,998	2,078
Operating Profit	248	404	321	286	269	265	262	289
OPM %	15%	21%	14%	11%	12%	12%	12%	12%
Other Income	9	7	5	2	4	14	3	0
Interest	36	26	23	36	33	32	28	26
Depreciation	47	48	47	47	48	48	56	59
Profit before tax	175	338	256	205	192	199	181	204
Tax %	22%	24%	24%	25%	26%	21%	7%	—
Net Profit	136	258	195	153	142	157	169	171
EPS in Rs	14.56	27.65	21.06	16.50	15.43	17.24	18.54	18.79
Dividend Payout %	3%	9%	5%	6%	6%	6%	11%	—

AARTIDRUGS balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	24	23	93	93	93	92	91	91
Reserves	495	598	766	880	1,022	1,083	1,160	1,314
Borrowings	471	378	336	519	535	475	516	421
Other Liabilities	384	471	442	543	546	522	506	556
Total Liabilities	1,373	1,471	1,637	2,035	2,196	2,172	2,273	2,382
Fixed Assets	586	612	631	649	634	722	761	971
CWIP	32	11	16	60	161	222	273	106
Investments	19	20	24	28	29	30	42	72
Other Assets	736	828	966	1,297	1,372	1,198	1,196	1,232
Total Assets	1,373	1,471	1,637	2,035	2,196	2,172	2,273	2,382

AARTIDRUGS cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	147	196	154	40	162	337	220	254
Cash from Investing Activity	-59	-29	-69	-125	-131	-187	-135	-128
Cash from Financing Activity	-87	-168	-85	84	-31	-149	-85	-126
Net Cash Flow	1	-1	-0	-1	0	1	1	0
Free Cash Flow	87	164	80	-87	31	148	83	152
CFO/OP	87%	94%	60%	37%	76%	144%	103%	93%

AARTIDRUGS shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	55.64%	55.38%	55.48%	55.23%	54.72%	55.03%	55.03%	54.43%
FIIs	2.50%	2.28%	2.25%	2.26%	2.68%	2.15%	1.57%	1.52%
DIIs	7.83%	8.77%	9.70%	9.94%	9.90%	10.12%	10.22%	10.29%
Public	34.01%	33.58%	32.57%	32.58%	32.70%	32.71%	33.19%	33.76%
No. of Shareholders	1,90,281	1,76,006	1,69,761	1,60,260	1,52,252	1,48,363	1,44,946	1,43,476

AARTIDRUGS key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	110	104	96	115	117	104	118	118
Inventory Days	86	107	125	120	102	107	106	103
Days Payable	86	110	94	103	89	96	97	105
Cash Conversion Cycle	109	101	127	133	130	115	127	116
Working Capital Days	46	60	83	68	73	79	79	80
ROCE %	17%	20%	33%	21%	15%	14%	14%	12%

AARTIDRUGSUpdated 13 Oct 2026, 2:48

Aarti Drugs Ltd.

AARTIDRUGSUpdated 13 Oct 2026, 2:48

Market Cap

₹3,775Cr.

Current Price

₹414

High / Low

₹534/319

Stock P/E

21.8

ROE12.7%

ROCE11.7%

Book Value₹154

Face Value₹10.0

Dividend Yield0.48%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	592	8	520	1	12	53	25	40	4.27
Sep 2023	578	8	512	1	12	47	26	35	3.76
Dec 2023	538	7	478	2	12	43	26	32	3.44
Mar 2024	560	8	490	1	12	50	27	36	3.93
Jun 2024	493	7	439	0	12	35	23	27	2.93
Sep 2024	543	7	484	0	12	41	26	30	3.33
Dec 2024	515	8	454	11	12	52	26	39	4.22
Mar 2025	623	7	534	2	12	71	13	61	6.74
Jun 2025	521	7	457	0	12	45	-7	49	5.33
Sep 2025	579	6	504	0	14	56	25	42	4.58
Dec 2025	529	7	486	1	15	22	-56	34	3.71
Mar 2026	632	7	552	1	15	59	23	45	4.93
Jun 2026	627	7	536	-2	15	68	25	51	5.57

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	1087	42	915	1	31	100	22	78	8.01
Mar 2016	1076	47	900	0	36	93	29	66	6.84
Mar 2017	1089	38	910	4	37	108	30	75	7.91
Mar 2018	1140	36	955	1	38	112	35	73	7.78
Mar 2019	1454	41	1252	6	40	128	32	87	9.25
Mar 2020	1635	36	1387	9	47	175	22	136	14.56
Mar 2021	1915	26	1511	7	48	338	24	258	27.65
Mar 2022	2251	23	1930	5	47	256	24	195	21.06
Mar 2023	2498	36	2212	2	47	205	25	153	16.5
Mar 2024	2267	33	1998	4	48	192	26	142	15.43
Mar 2025	2174	32	1908	14	48	199	21	157	17.24
Mar 2026	2260	28	1998	3	56	181	7	169	18.54
TTM	2367	26	2078	0	59	204	—	171	18.79

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	54.43%
FIIs	1.52%
DIIs	10.29%
Public	33.76%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Sep 2023	58.57%	2.33%	5.32%	33.78%
Dec 2023	57.47%	2.1%	5.26%	35.16%
Mar 2024	57.13%	2.56%	5.99%	34.3%
Jun 2024	55.67%	2.95%	7.35%	34.01%
Sep 2024	55.64%	2.5%	7.83%	34.01%
Dec 2024	55.38%	2.28%	8.77%	33.58%
Mar 2025	55.48%	2.25%	9.7%	32.57%
Jun 2025	55.23%	2.26%	9.94%	32.58%
Sep 2025	54.72%	2.68%	9.9%	32.7%
Dec 2025	55.03%	2.15%	10.12%	32.71%
Mar 2026	55.03%	1.57%	10.22%	33.19%
Jun 2026	54.43%	1.52%	10.29%	33.76%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	24	279	435	228	967	431	13	11	511	967
Mar 2016	24	326	465	240	1055	463	34	11	547	1055
Mar 2017	24	363	448	281	1116	542	14	18	541	1116
Mar 2018	24	410	517	366	1316	564	28	17	707	1316
Mar 2019	24	495	471	384	1373	586	32	19	736	1373
Mar 2020	23	598	378	471	1471	612	11	20	828	1471
Mar 2021	93	766	336	442	1637	631	16	24	966	1637
Mar 2022	93	880	519	543	2035	649	60	28	1297	2035
Mar 2023	93	1022	535	546	2196	634	161	29	1372	2196
Mar 2024	92	1083	475	522	2172	722	222	30	1198	2172
Mar 2025	91	1160	516	506	2273	761	273	42	1196	2273
Mar 2026	91	1314	421	556	2382	971	106	72	1232	2382

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	107	-102	-5	-1
Mar 2016	125	-87	-37	1
Mar 2017	174	-96	-78	0
Mar 2018	62	-71	9	0
Mar 2019	147	-59	-87	1
Mar 2020	196	-29	-168	-1
Mar 2021	154	-69	-85	0
Mar 2022	40	-125	84	-1
Mar 2023	162	-131	-31	0
Mar 2024	337	-187	-149	1
Mar 2025	220	-135	-85	1
Mar 2026	254	-128	-126	0

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	103	109	93	117	110	104	96	115	117	104	118	118
Inventory Days	77	87	101	132	86	107	125	120	102	107	106	103
Days Payable	75	85	91	125	86	110	94	103	89	96	97	105
Cash Conversion Cycle	105	110	103	124	109	101	127	133	130	115	127	116
Working Capital Days	13	21	26	33	46	60	83	68	73	79	79	80
ROCE %	21%	18%	17%	17%	17%	20%	33%	21%	15%	14%	14%	12%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of AARTI DRUGS LTD. (AARTIDRUGS)?

The reported market capitalisation for AARTI DRUGS LTD. (AARTIDRUGS) is ₹3,775Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of AARTIDRUGS?

The current price shown for AARTI DRUGS LTD. (AARTIDRUGS) on Fincrux is ₹414 with a 52-week high/low of ₹534/319.

What is the P/E ratio of AARTI DRUGS LTD. (AARTIDRUGS)?

The stock P/E for AARTI DRUGS LTD. (AARTIDRUGS) is 21.8 on Fincrux, with ROE at 12.7% and ROCE at 11.7%.

What were AARTIDRUGS latest quarterly results?

For Jun 2026, AARTI DRUGS LTD. (AARTIDRUGS) reported sales ₹627 Cr and net profit ₹51 Cr (figures in ₹ crore unless noted).

What are AARTIDRUGS annual sales and net profit?

For TTM, AARTI DRUGS LTD. (AARTIDRUGS) shows sales of ₹2,367 Cr and net profit of ₹171 Cr on the Fincrux profit & loss statement.

Who owns AARTI DRUGS LTD. (AARTIDRUGS)?

Latest shareholding for AARTI DRUGS LTD. (AARTIDRUGS) on Fincrux: Promoters 54.43% (Jun 2026), FIIs 1.52% (Jun 2026), DIIs 10.29% (Jun 2026), Public 33.76% (Jun 2026), No. of Shareholders 1,43,476% (Jun 2026).

Where can I find AARTI DRUGS LTD. (AARTIDRUGS) financials?

AARTI DRUGS LTD. (AARTIDRUGS) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show AARTIDRUGS balance sheet and cash flow?

Yes. The AARTI DRUGS LTD. (AARTIDRUGS) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 13 October 2026 at 2:48